<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743245</url>
  </required_header>
  <id_info>
    <org_study_id>AMIHOT III 22 October 2020</org_study_id>
    <nct_id>NCT04743245</nct_id>
  </id_info>
  <brief_title>SSO2 THERAPY: AMIHOT III STUDY</brief_title>
  <official_title>A Post Approval Study to Evaluate the Delivery of Hyperoxemic Super Saturated Oxygen Therapy for 60 Minutes in Anterior AMI Patients Compared to PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TherOx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TherOx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center randomized post-approval evaluation of delivery of intracoronary hyperoxemic&#xD;
      supersaturated Oxygen therapy for 60 minutes in anterior AMI patients with successful&#xD;
      reperfusion (via PCI) within 6 hours after onset of symptoms compared to standard therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year rate of Net Adverse Clinical Events (NACE)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in infarct size between SSO2 Therapy and standard therapy in patients</measure>
    <time_frame>2-7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">434</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>PCI with SSO2 therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>anterior AMI patients treated with PCI and stenting within 6 hours</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TherOx DownStream System</intervention_name>
    <description>SSO2 Therapy with Therox downstream System after Percutaneous Coronary Intervention (PCI)</description>
    <arm_group_label>PCI with SSO2 therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCI</intervention_name>
    <description>Standard Care of PCI</description>
    <arm_group_label>PCI with SSO2 therapy</arm_group_label>
    <arm_group_label>anterior AMI patients treated with PCI and stenting within 6 hours</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Pre-PCI:&#xD;
&#xD;
          1. The subject must be â‰¥18 years of age.&#xD;
&#xD;
          2. AMI must be anterior (ST-segment elevation &gt;1 mm in two or more contiguous leads&#xD;
             between V1 and V4 or new left bundle branch block).&#xD;
&#xD;
          3. The subject or legally authorized representative has been informed of the nature of&#xD;
             the study, agrees to its provisions and has been provided and signed written informed&#xD;
             consent, approved by the appropriate Institutional Review Board (IRB) or Ethics&#xD;
             Committee (EC).&#xD;
&#xD;
          4. Subject and his/her physician agree to all required follow-up procedures and visits.&#xD;
&#xD;
             ANGIOGRAPHIC INCLUSION CRITERIA: These are evaluated after the subject has provided&#xD;
             signed Informed Consent and has undergone cardiac catheterization and PCI if&#xD;
             indicated:&#xD;
&#xD;
          5. Based on coronary anatomy, PCI is indicated for revascularization of the culprit&#xD;
             lesion(s) with use of a commercially available coronary stent (bare metal or&#xD;
             drug-eluting, at operator discretion) in the LAD.&#xD;
&#xD;
          6. The primary stented infarct-related lesion(s) must be in the proximal and/or mid-LAD&#xD;
             coronary artery (other lesions in the LAD target vessel, including diagonal branches,&#xD;
             may be treated if clinically indicated).&#xD;
&#xD;
          7. Successful angioplasty is completed &lt;6 hrs from symptom onset, as documented by 30%&#xD;
             diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2&#xD;
             or 3 flow and no major complications such as perforation or shock.&#xD;
&#xD;
          8. Expected ability to place the SSO2 delivery catheter in the coronary ostium of the&#xD;
             left main coronary system to deliver SSO2 Therapy with stable, coaxial alignment.&#xD;
&#xD;
          9. Systemic arterial pO2 greater than or equal to 80 mmHg as measured by arterial blood&#xD;
             gas (may be repeated if low after supplemental O2 administration).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Pre-PCI:&#xD;
&#xD;
          1. Prior CABG surgery.&#xD;
&#xD;
          2. Prior myocardial infarction or known prior systolic dysfunction (e.g. due to&#xD;
             cardiomyopathy); this criterion does not include left ventricular dysfunction induced&#xD;
             by the acute MI.&#xD;
&#xD;
          3. An elective surgical procedure is planned during the first 30 days post-enrollment.&#xD;
&#xD;
          4. Subjects who previously underwent coronary stent implantation and in whom coronary&#xD;
             angiography demonstrates stent thrombosis to be the cause of the anterior AMI.&#xD;
&#xD;
          5. Subjects who have previously undergone an angioplasty or stenting procedure in the&#xD;
             left anterior descending coronary artery.&#xD;
&#xD;
          6. Contraindication to MRI imaging, including any of the following:&#xD;
&#xD;
               1. Non-MRI compatible cardiac pacemaker or implantable defibrillator;&#xD;
&#xD;
               2. Non-MRI compatible aneurysm clip or other metallic implants;&#xD;
&#xD;
               3. Neural Stimulator (i.e., TENS unit);&#xD;
&#xD;
               4. Any implanted or magnetically activated device (insulin pump);&#xD;
&#xD;
               5. Any type of non-MRI compatible ear implant;&#xD;
&#xD;
               6. Metal shavings in the orbits;&#xD;
&#xD;
               7. Any indwelling metallic foreign body, shrapnel, or bullet;&#xD;
&#xD;
               8. Any condition contraindicating MRI, including claustrophobia;&#xD;
&#xD;
               9. Inability to follow breath hold instructions or to maintain a breath hold for &gt;15&#xD;
                  seconds; and&#xD;
&#xD;
              10. Known hypersensitivity or contraindication to gadolinium contrast.&#xD;
&#xD;
          7. Known impaired renal function (creatinine clearance &lt;30 ml/min/1.73 m2 by the MDRD&#xD;
             formula) or on dialysis.&#xD;
&#xD;
          8. Known platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3 or a known Hgb &lt;10 g/dL.&#xD;
&#xD;
          9. Subject has active bleeding or a history of bleeding diathesis or coagulopathy&#xD;
             (including heparin induced thrombocytopenia), or refusal to receive blood transfusions&#xD;
             if necessary.&#xD;
&#xD;
         10. History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic&#xD;
             stroke.&#xD;
&#xD;
         11. Stroke or transient ischemic attack within the past six (6) months, or any permanent&#xD;
             neurological defect.&#xD;
&#xD;
         12. Gastrointestinal or genitourinary bleeding within the last two (2) months, or any&#xD;
             major surgery (including CABG) within six weeks of enrollment.&#xD;
&#xD;
         13. Subject has received any organ transplant or is on a waiting list for any organ&#xD;
             transplant.&#xD;
&#xD;
         14. Subject has other medical illness (e.g., cancer, dementia) or known history of&#xD;
             substance abuse (alcohol, cocaine, heroin, etc.) that may cause non-compliance with&#xD;
             the protocol, confound the data interpretation, or is associated with life expectancy&#xD;
             of less than one year.&#xD;
&#xD;
         15. Subject has a known hypersensitivity or contraindication to any of the required study&#xD;
             medications or contrast that cannot be adequately premedicated.&#xD;
&#xD;
         16. Subjects presenting with or developing in the cath lab prior to completion of the PCI&#xD;
             procedure any of the following conditions: cardiogenic shock (SBP &lt;80 mmHg for &gt;30&#xD;
             minutes), or requiring IV pressors or emergent placement of an intra-aortic balloon&#xD;
             pump (IABP), Impella, or other hemodynamic support for hypotension treatment, or&#xD;
             cardiopulmonary resuscitation for &gt;10 minutes, or ventricular fibrillation or&#xD;
             tachycardia requiring cardioversion or defibrillation.&#xD;
&#xD;
         17. Severe known cardiac valvular stenosis or insufficiency, pericardial disease, or&#xD;
             cardiomyopathy.&#xD;
&#xD;
         18. Subject is a member of a vulnerable population or has any significant medical or&#xD;
             social condition which in the investigator's opinion may interfere with the subject's&#xD;
             participation in the study or ability to comply with follow-up procedures, including&#xD;
             MRI (e.g. alcoholism, dementia, lives far from the research center, etc.).&#xD;
&#xD;
         19. Current participation in other investigational device or drug study that has not&#xD;
             reached its primary endpoint.&#xD;
&#xD;
         20. Previous enrollment in this study.&#xD;
&#xD;
             ANGIOGRAPHIC EXCLUSION CRITERIA: These are evaluated after the subject has provided&#xD;
             signed Informed Consent and has undergone cardiac catheterization and PCI if&#xD;
             indicated:&#xD;
&#xD;
         21. Treatment during the index procedure of any lesion in either the left main, LCX&#xD;
             (including the ramus), and/or RCA.&#xD;
&#xD;
         22. Post-index procedure planned intervention within 7 days (i.e., PCI of non-target&#xD;
             lesions in any vessel, or CABG). Note: Planned revascularization (PCI or bypass) of a&#xD;
             non-target lesion &gt;7 days following the index procedure and after performance of the&#xD;
             2-7day MRI is allowed.&#xD;
&#xD;
         23. Anterior MI is due to thrombosis within or adjacent to a previously implanted stent.&#xD;
&#xD;
         24. Left ventriculography (mandatory before or after PCI, but in all cases before&#xD;
             randomization) demonstrates severe mitral regurgitation, a ventricular septal defect,&#xD;
             a pseudoaneurysm, aortic dissection or other mechanical complications of MI.&#xD;
&#xD;
         25. Any left main coronary artery stenosis &gt;20%.&#xD;
&#xD;
         26. Any untreated LAD or diagonal branch lesion is present with diameter stenosis &gt; 50% in&#xD;
             a vessel with reference vessel diameter &gt; 2.0 mm (visually estimated).&#xD;
&#xD;
         27. Presence of a non-stented coronary dissection with NHLBI grade &gt;B upon completion of&#xD;
             the PCI procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeffrey Creech, PhD</last_name>
    <phone>3233096949</phone>
    <email>jcreech@zoll.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shailaja Lakma</last_name>
    <phone>9253367743</phone>
    <email>slakma@zoll.com</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

